Dermatomyositis and immune-Mediated Necrotizing Myopathies: A window on Autoimmunity and Cancer

Frontiers in Immunology

Volumn 8, Issue AUG, 2017, Pages

  Aussy, Audrey ^a   Boyer, Olivier ^a   Cordel, Nadège ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b University of the French West Indies   (Guadeloupe)

Author keywords

Autoantibody; Autoimmunity; Cancer; Myositis; TIF1gamma

Indexed keywords

AUTOANTIBODY; CD31 ANTIGEN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MICRORCHIDIA3; NERVE CELL ADHESION MOLECULE; PROTEIN; STEROID RECEPTOR COACTIVATOR 1; TRANSCRIPTION ACCESSORY FACTOR 1 GAMMA; TRANSFORMING GROWTH FACTOR BETA; TRIPARTITE MOTIF PROTEIN 33; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CANCER RISK; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DNA REPAIR; DYSPHAGIA; ELECTROMYOGRAPHY; ERYTHROPOIESIS; GENE; GENE MUTATION; GENE OVEREXPRESSION; HISTOLOGY; HMGCR GENE; HUMAN; HYPERKERATOSIS; IMMUNE MEDIATED INJURY; MICROANGIOPATHY; MORC3 GENE; MUSCLE BIOPSY; MYOPATHY; NECROTIZING AUTOIMMUNE MYOPATHY; NEOPLASM; OUTCOME ASSESSMENT; PREVALENCE; RAYNAUD PHENOMENON; REVIEW; UPREGULATION;

EID: 85027959548     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00992     Document Type: Review

References (148)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 292(7):344-7. doi:10.1056/NEJM197502132920706
2. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med (2005) 165(20):2337-44. doi:10.1001/archinte.165.20.2337
3. Shah AA, Casciola-Rosen L, Rosen A. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol (2015) 67(2):317-26. doi:10.1002/art.38928
4. Egiziano G, Bernatsky S, Shah AA. Cancer and autoimmunity: harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol (2016) 30(1):53-62. doi:10.1016/j.berh.2016.03.001
5. Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis (2014) 73(1):138-42. doi:10.1136/ annrheumdis-2012-202099
6. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis (2014) 73(6):1151-6. doi:10.1136/annrheumdis-2013-203305
7. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun (2013) 42:130-5. doi:10.1016/j. jaut.2012.12.009
8. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis (2007) 2:22. doi:10.1186/1750-1172-2-22
9. Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol (1995) 38(1):102-10. doi:10.1002/ana.410380117
10. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology (2013) 2(12):e27384. doi:10.4161/onci.27384
11. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2014) 343(6167):152-7. doi:10.1126/science.1246886.
12. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol (1995) 38(5): 705-13. doi:10.1002/ana.410380504
13. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord (2004) 14(5):337-45. doi:10.1016/j.nmd.2004.02.006
14. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) (2005) 84(4):231-49. doi:10.1097/01.md.0000173991.74008.b0
15. Lundberg IE. New ways to subclassify patients with myositis. J Intern Med (2016) 280(1):4-7. doi:10.1111/joim.12515
16. Lundberg IE, Miller FW, Tjärnlund A, Bottai M. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med (2016) 280(1):39-51. doi:10.1111/joim.12524
17. Simon JP, Marie I, Jouen F, Boyer O, Martinet J. Autoimmune myopathies: where do we stand? Front Immunol (2016) 7:234. doi:10.3389/ fimmu.2016.00234
18. Oddis CV, Conte CG, Steen VD, Medsger TA. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol (1990) 17(10):1329-34.
19. Francès C, Bessis D. Dermatomyosite. Manifestations dermatologiques des connectivites, vasculites et affections systémiques apparentées. 2nd Ed. Paris: Springer (2012). p. 1-15.
20. McKee P, Calonje E, Granter S. Pathology of the Skin with Clinical Correlations. 3rd ed. Philadelphia: Elsevier/Mosby (2005).
21. Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol (1999) 11(6):475-82. doi:10.1097/00002281-199911000-00005
22. Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun (2014) 4(8-49):122-7. doi:10.1016/j.jaut.2013.11.005
23. Gitiaux C, Kostallari E, Lafuste P, Authier FJ, Christov C, Gherardi RK. Whole microvascular unit deletions in dermatomyositis. Ann Rheum Dis (2013) 72(3):445-52. doi:10.1136/annrheumdis-2012-201822
24. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol (2005) 57(5):664-78. doi:10.1002/ana.20464
25. Wong D, Kea B, Pesich R, Higgs BW, Zhu W, Brown P, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One (2012) 7(1):e29161. doi:10.1371/journal. pone.0029161
26. Huard C, Gullà SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon ß in dermatomyositis. Br J Dermatol (2017) 176(5):1224-30. doi:10.1111/bjd.15006
27. Hunger RE, Dürr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology (2001) 202(2):123-6. doi:10.1159/000051611
28. Burnouf M, Mahé E, Verpillat P, Descamps V, Lebrun-Vignes B, Picard-Dahan C, et al. [Cutaneous necrosis is predictive of cancer in adult dermatomyositis]. Ann Dermatol Venereol (2003) 130(3):313-6.
29. Tersiguel AC, Longueville C, Beltan E, Vincent T, Tressières B, Cordel N. [Prevalence of cancer in the Afro-Caribbean population presenting dermatomyositis and anti-synthetase syndrome: a preliminary study conducted at Pointe-à-Pitre University Hospital, 2000-2012]. Ann Dermatol Venereol (2014) 141(10):575-80. doi:10.1016/j.annder.2014.04.112
30. Kankeleit H. über primaire nichteitrige polymyositis. Dtsch Arch Klin Med (1916) 120:335-9.
31. Stertz G. Polymyositis. Berl Klin Wochenschau (1916) 53:489.
32. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (2001) 357(9250):96-100. doi:10.1016/S0140-6736(00)03540-6
33. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer (2001) 85(1):41-5. doi:10.1054/ bjoc.2001.1699
34. András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol (2008) 35(3):438-44.
35. Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep (2011) 13(3):208-15. doi:10.1007/s11926-011-0169-7
36. Airio A, Pukkala E, Isomäki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol (1995) 22(7): 1300-3.
37. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol (2002) 41(11):729-34. doi:10.1046/j.1365-4362.2002. 01648.x
38. Yang Z, Lin F, Qin B, Liang Y, Zhong R. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol (2015) 42(2): 282-91. doi:10.3899/jrheum.140566
39. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med (2016) 280(1):8-23. doi:10.1111/joim.12451
40. Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, et al. Anti-Mi-2 antibodies. Autoimmunity (2005) 38(1): 79-83. doi:10.1080/08916930400022681
41. Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum (2006) 55(5):791-8. doi:10.1002/art.22237
42. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis (2007) 66(10):1345-9. doi:10.1136/ard.2006. 068502
43. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol (2011) 65(1):25-34. doi:10.1016/j.jaad.2010.09.016
44. Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) (2013) 65(8):1307-15. doi:10.1002/acr.21992
45. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol (2013) 23(3):496-502. doi:10.1007/s10165-012-0663-4
46. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis (2009) 68(10):1621-5. doi:10.1136/ard.2008.097162
47. Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity (2013) 46(4):279-84. doi:10.3109/08916934.2012.755958
48. Ge Y, Lu X, Shu X, Peng Q, Wang G. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep (2017) 7(1):188. doi:10.1038/s41598-017-00240-6
49. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum (2006) 54(11):3682-9. doi:10.1002/art.22164
50. Trallero-Araguás E, Rodrigo-Pendás J, Selva-O'Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum (2012) 64(2):523-32. doi:10.1002/art.33379
51. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum (2009) 60(6): 1807-14. doi:10.1002/art.24547
52. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?. Arthritis Rheum (2013) 65(11):2954-62. doi:10.1002/ art.38093
53. Basharat P, Lahouti HA, Mammen AL, Pinal-Fernandez I, Bichile T, Lloyd TE, et al. Diabetes and atorvastatin are potential risk factors for statin-associated myopathy with autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase. American College of Rheumatology Meeting 2014. Boston, USA (2014).
54. Limaye V, Bundell C, Hollingsworth P, Rojana-Udomsart A, Mastaglia F, Blumbergs P, et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve (2015) 52(2):196-203. doi:10.1002/mus.24541
55. Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol (2015) 52(1):20-33. doi:10.1007/s12016-015-8511-x
56. Allenbach Y, Keraen J, Bouvier AM, Jooste V, Champtiaux N, Hervier B, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain (2016) 139(Pt 8):2131-5. doi:10.1093/brain/aww054
57. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) (2007) 46(1):25-8. doi:10.1093/ rheumatology/kel161
58. Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med (2016) 280(1):24-38. doi:10.1111/joim.12444
59. Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M, et al. Anti-TIF1-? antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology (2016) 87(3):299-308. doi:10.1212/WNL.0000000000002863
60. Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1? antibodies in adults with dermatomyositis. J Am Acad Dermatol (2015) 72(3):449-55. doi:10.1016/j.jaad.2014. 12.009
61. Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol (2016) 28(6):636-44. doi:10.1097/BOR.0000000000000329
62. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) (2008) 47(3):324-8. doi:10.1093/rheumatology/kem359
63. Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, et al. Brief report: association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis. Arthritis Rheumatol (2016) 68(3):761-8. doi:10.1002/ art.39466
64. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther (2012) 14(2):R97. doi:10.1186/ar3822
65. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum (2010) 62(9):2757-66. doi:10.1002/art.27572
66. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum (2011) 63(3):713-21. doi:10.1002/art.30156
67. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis (2012) 71(5):710-3. doi:10.1136/annrheumdis-2011-200697
68. Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep (2015) 17(12):72. doi:10.1007/s11926-015-0548-6
69. Kadoya M, Hida A, Hashimoto Maeda M, Taira K, Ikenaga C, Uchio N, et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm (2016) 3(6):e290. doi:10.1212/NXI.0000000000000290
70. Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken) (2017). doi:10.1002/acr.23210
71. Allenbach Y, Benveniste O. [Autoantibody profile in myositis]. Rev Med Interne (2013) 35(7):437-43. doi:10.1016/j.revmed.2013.12.006
72. Allenbach Y, Benveniste O. Acquired necrotizing myopathies. Curr Opin Neurol (2013) 26(5):554-60. doi:10.1097/WCO.0b013e328364e9d9
73. Venturini L, You J, Stadler M, Galien R, Lallemand V, Koken MH, et al. TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene (1999) 18(5):1209-17. doi:10.1038/sj.onc.1202655
74. Ferri F, Parcelier A, Petit V, Gallouet AS, Lewandowski D, Dalloz M, et al. TRIM33 switches off Ifnb1 gene transcription during the late phase of macrophage activation. Nat Commun (2015) 6:8900. doi:10.1038/ ncomms9900 75. Sedgwick GG, Townsend K, Martin A, Shimwell NJ, Grand RJ, Stewart GS, et al. Transcriptional intermediary factor 1? binds to the anaphase-promoting complex/cyclosome and promotes mitosis. Oncogene (2013) 32(39):4622-33. doi:10.1038/onc.2012.501
75. Sedgwick GG, Townsend K, Martin A, Shimwell NJ, Grand RJ, Stewart GS, et al. Transcriptional intermediary factor 1? binds to the anaphase-promoting complex/cyclosome and promotes mitosis. Oncogene (2013) 32(39):4622-33. doi:10.1038/onc.2012.501
76. Pommier RM, Gout J, Vincent DF, Alcaraz LB, Chuvin N, Arfi V, et al. TIF1? suppresses tumor progression by regulating mitotic checkpoints and chromosomal stability. Cancer Res (2015) 75(20):4335-50. doi:10.1158/0008-5472.CAN-14-3426
77. Li DQ, Nair SS, Kumar R. The MORC family: new epigenetic regulators of transcription and DNA damage response. Epigenetics (2013) 8(7):685-93. doi:10.4161/epi.24976
78. Kimura Y, Sakai F, Nakano O, Kisaki O, Sugimoto H, Sawamura T, et al. The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem (2002) 277(23):20611-7. doi:10.1074/jbc. M201440200
79. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A (2004) 101(16):6062-7. doi:10.1073/pnas. 0400782101
80. Hong G, Qiu H, Wang C, Jadhav G, Wang H, Tickner J, et al. The emerging role of MORC family proteins in cancer development and bone homeostasis. J Cell Physiol (2017) 232(5):928-34. doi:10.1002/jcp.25665 81. Durr IF, Rudney H. The reduction of beta-hydroxy-beta-methyl-glutaryl coenzyme A to mevalonic acid. J Biol Chem (1960) 235:2572-8.
81. Durr IF, Rudney H. The reduction of beta-hydroxy-beta-methyl-glutaryl coenzyme A to mevalonic acid. J Biol Chem (1960) 235:2572-8.
82. Roitelman J, Simoni RD. Distinct sterol and nonsterol signals for the regulated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem (1992) 267(35):25264-73.
83. Stormo C, Kringen MK, Grimholt RM, Berg JP, Piehler AP. A novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) splice variant with an alternative exon 1 potentially encoding an extended N-terminus. BMC Mol Biol (2012) 13:29. doi:10.1186/1471-2199-13-29
84. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol (2009) 36(11):2547-51. doi:10.3899/jrheum.090461
85. Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) (2012) 51(7):1181-7. doi:10.1093/rheumatology/kes033
86. Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, et al. Increased frequency of DRB111:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) (2012) 64(8):1233-7. doi:10.1002/acr.21671
87. Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, et al. Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies are associated with DRB107:01 and severe myositis in pediatric myositis patients. Arthritis Care Res (Hoboken) (2017) 69(7):1088-94. doi:10.1002/acr.23113
88. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve (2010) 41(2):185-90. doi:10.1002/mus.21486
89. Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) (2014) 93(3):150-7. doi:10.1097/MD.0000000000000028 90. Watanabe Y, Suzuki S, Nishimura H, Murata KY, Kurashige T, Ikawa M, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore) (2015) 94(4):e416. doi:10.1097/MD.0000000000000416 91. Bergua C, Chiavelli H, Simon JP, Boyer O, Jouen F, Stenzel W, et al. Immune-mediated necrotizing myopathy. Z Rheumatol (2016) 75(2):151-6. doi:10.1007/s00393-015-0029-3
90. Watanabe Y, Suzuki S, Nishimura H, Murata KY, Kurashige T, Ikawa M, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore) (2015) 94(4):e416. doi:10.1097/MD.0000000000000416
91. Bergua C, Chiavelli H, Simon JP, Boyer O, Jouen F, Stenzel W, et al. Immune-mediated necrotizing myopathy. Z Rheumatol (2016) 75(2):151-6. doi:10.1007/s00393-015-0029-3
92. Liang WC, Uruha A, Suzuki S, Murakami N, Takeshita E, Chen WZ, et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxford) (2017) 56(2):287-93. doi:10.1093/rheumatology/kew386
93. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer (2011) 11(11):792-804. doi:10.1038/nrc3139
94. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripartite motif family identifies cell compartments. EMBO J (2001) 20(9):2140-51. doi:10.1093/emboj/20.9.2140
95. Agricola E, Randall RA, Gaarenstroom T, Dupont S, Hill CS. Recruitment of TIF1? to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell (2011) 43(1):85-96. doi:10.1016/j.molcel.2011.05.020
96. Andrieux G, Fattet L, Le Borgne M, Rimokh R, Théret N. Dynamic regulation of Tgf-B signaling by Tif1?: a computational approach. PLoS One (2012) 7(3):e33761. doi:10.1371/journal.pone.0033761
97. Dupont S, Inui M, Newfeld SJ. Regulation of TGF-ß signal transduction by mono-and deubiquitylation of Smads. FEBS Lett (2012) 586(14): 1913-20. doi:10.1016/j.febslet.2012.03.037
98. Morsut L, Yan KP, Enzo E, Aragona M, Soligo SM, Wendling O, et al. Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo. Development (2010) 137(15):2571-8. doi:10.1242/ dev.053801
99. Falk S, Joosten E, Kaartinen V, Sommer L. Smad4 and Trim33/Tif1? redundantly regulate neural stem cells in the developing cortex. Cereb Cortex (2014) 24(11):2951-63. doi:10.1093/cercor/bht149
100. Lane J, Yumoto K, Azhar M, Ninomiya-Tsuji J, Inagaki M, Hu Y, et al. Tak1, Smad4 and Trim33 redundantly mediate TGF-ß3 signaling during palate development. Dev Biol (2015) 398(2):231-41. doi:10.1016/j. ydbio.2014.12.006
101. Massagué J, Xi Q. TGF-ß control of stem cell differentiation genes. FEBS Lett (2012) 586(14):1953-8. doi:10.1016/j.febslet.2012.03.023
102. Hesling C, Lopez J, Fattet L, Gonzalo P, Treilleux I, Blanchard D, et al. Tif1? is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development (2013) 140(1):167-75. doi:10.1242/dev.085068
103. Guo J, Qin W, Xing Q, Gao M, Wei F, Song Z, et al. TRIM33 is essential for osteoblast proliferation and differentiation via BMP pathway. J Cell Physiol (2017) 232(11):3158-69. doi:10.1002/jcp.25769
104. Chrétien ML, Legouge C, Martin RZ, Hammann A, Trad M, Aucagne R, et al. Trim33/Tif1? is involved in late stages of granulomonopoiesis in mice. Exp Hematol (2016) 44(8):727-39.e6. doi:10.1016/j. exphem.2016.04.009
105. Doisne JM, Bartholin L, Yan KP, Garcia CN, Duarte N, Le Luduec JB, et al. iNKT cell development is orchestrated by different branches of TGF-beta signaling. J Exp Med (2009) 206(6):1365-78. doi:10.1084/jem.20090127
106. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massagué J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell (2006) 125(5):929-41. doi:10.1016/j. cell.2006.03.045
107. Bai X, Trowbridge JJ, Riley E, Lee JA, DiBiase A, Kaartinen VM, et al. TiF1-gamma plays an essential role in murine hematopoiesis and regulates transcriptional elongation of erythroid genes. Dev Biol (2013) 373(2):422-30. doi:10.1016/j.ydbio.2012.10.008
108. Quéré R, Saint-Paul L, Carmignac V, Martin RZ, Chrétien ML, Largeot A, et al. Tif1? regulates the TGF-ß1 receptor and promotes physiological aging of hematopoietic stem cells. Proc Natl Acad Sci U S A (2014) 111(29):10592-7. doi:10.1073/pnas.1405546111
109. Kusy S, Gault N, Ferri F, Lewandowski D, Barroca V, Jaracz-Ros A, et al. Adult hematopoiesis is regulated by TIF1?, a repressor of TAL1 and PU.1 transcriptional activity. Cell Stem Cell (2011) 8(4):412-25. doi:10.1016/j. stem.2011.02.005
110. Monteiro R, Pouget C, Patient R. The gata1/pu.1 lineage fate paradigm varies between blood populations and is modulated by tif1?. EMBO J (2011) 30(6):1093-103. doi:10.1038/emboj.2011.34
111. Gallouet AS, Ferri F, Petit V, Parcelier A, Lewandowski D, Gault N, et al. Macrophage production and activation are dependent on TRIM33. Oncotarget (2017) 8(3):5111-22. doi:10.18632/oncotarget.13872
112. Weng L, Mitoma H, Trichot C, Tricot C, Bao M, Liu Y, et al. The E3 ubiquitin ligase tripartite motif 33 is essential for cytosolic RNA-induced NLRP3 inflammasome activation. J Immunol (2014) 193(7):3676-82. doi:10.4049/ jimmunol.1401448
113. Howard PW, Ransom DG, Maurer RA. Transcription intermediary factor 1gamma decreases protein expression of the transcriptional cofactor, LIM-domain-binding 1. Biochem Biophys Res Commun (2010) 396(3):674-8. doi:10.1016/j.bbrc.2010.04.160
114. Kulkarni A, Oza J, Yao M, Sohail H, Ginjala V, Tomas-Loba A, et al. Tripartite motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with amplified in liver cancer 1 (ALC1) protein. J Biol Chem (2013) 288(45):32357-69. doi:10.1074/jbc.M113.459164
115. Oza J, Ganguly B, Kulkarni A, Ginjala V, Yao M, Ganesan S. A novel role of chromodomain protein CBX8 in DNA damage response. J Biol Chem (2016) 291(44):22881-93. doi:10.1074/jbc.M116.725879
116. Xue J, Chen Y, Wu Y, Wang Z, Zhou A, Zhang S, et al. Tumour suppressor TRIM33 targets nuclear ß-catenin degradation. Nat Commun (2015) 6:6156. doi:10.1038/ncomms7156
117. Hesling C, Fattet L, Teyre G, Jury D, Gonzalo P, Lopez J, et al. Antagonistic regulation of EMT by TIF1? and Smad4 in mammary epithelial cells. EMBO Rep (2011) 12(7):665-72. doi:10.1038/embor.2011.78
118. Ikeuchi Y, Dadakhujaev S, Chandhoke AS, Huynh MA, Oldenborg A, Ikeuchi M, et al. TIF1? protein regulates epithelial-mesenchymal transition by operating as a small ubiquitin-like modifier (SUMO) E3 ligase for the transcriptional regulator SnoN1. J Biol Chem (2014) 289(36):25067-78. doi:10.1074/jbc.M114.575878
119. Herquel B, Ouararhni K, Davidson I. The TIF1a-related TRIM cofactors couple chromatin modifications to transcriptional regulation, signaling and tumor suppression. Transcription (2011) 2(5):231-6. doi:10.4161/ trns.2.5.17725
120. Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M, et al. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A (2011) 108(20):8212-7. doi:10.1073/ pnas.1101544108
121. Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, et al. Transcription intermediary factor 1? is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest (2011) 121(6):2361-70. doi:10.1172/JCI45213
122. Vincent DF, Yan KP, Treilleux I, Gay F, Arfi V, Kaniewski B, et al. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet (2009) 5(7):e1000575. doi:10.1371/journal. pgen.1000575
123. Vincent DF, Gout J, Chuvin N, Arfi V, Pommier RM, Bertolino P, et al. Tif1? suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway. Am J Pathol (2012) 180(6):2214-21. doi:10.1016/j. ajpath.2012.02.006
124. Ligr M, Wu X, Daniels G, Zhang D, Wang H, Hajdu C, et al. Imbalanced expression of Tif1? inhibits pancreatic ductal epithelial cell growth. Am J Cancer Res (2014) 4(3):196-210.
125. Ding ZY, Jin GN, Wang W, Chen WX, Wu YH, Ai X, et al. Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Hepatology (2014) 60(5):1620-36. doi:10.1002/hep.27273
126. Jingushi K, Ueda Y, Kitae K, Hase H, Egawa H, Ohshio I, et al. miR-629 targets TRIM33 to promote TGFß/Smad signaling and metastatic phenotypes in ccRCC. Mol Cancer Res (2015) 13(3):565-74. doi:10.1158/1541-7786. MCR-14-0300
127. Wang L, Yang H, Lei Z, Zhao J, Chen Y, Chen P, et al. Repression of TIF1? by SOX2 promotes TGF-ß-induced epithelial-mesenchymal transition in non-small-cell lung cancer. Oncogene (2016) 35(7):867-77. doi:10.1038/ onc.2015.141
128. Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, et al. TIF1? interferes with TGFß1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. BMC Cancer (2015) 15:453. doi:10.1186/ s12885-015-1471-y
129. Jain S, Singhal S, Francis F, Hajdu C, Wang JH, Suriawinata A, et al. Association of overexpression of TIF1? with colorectal carcinogenesis and advanced colorectal adenocarcinoma. World J Gastroenterol (2011) 17(35):3994-4000. doi:10.3748/wjg.v17.i35.3994
130. Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M, et al. Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell (2007) 18(5):1701-9. doi:10.1091/ mbc.E06-08-0747
131. Mimura Y, Takahashi K, Kawata K, Akazawa T, Inoue N. Two-step colocalization of MORC3 with PML nuclear bodies. J Cell Sci (2010) 123 (Pt 12):2014-24. doi:10.1242/jcs.063586
132. He F, Umehara T, Saito K, Harada T, Watanabe S, Yabuki T, et al. Structural insight into the zinc finger CW domain as a histone modification reader. Structure (2010) 18(9):1127-39. doi:10.1016/j.str.2010.06.012
133. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell (2012) 22(5):656-67. doi:10.1016/j.ccr.2012.08.027
134. Jadhav G, Teguh D, Kenny J, Tickner J, Xu J. Morc3 mutant mice exhibit reduced cortical area and thickness, accompanied by altered haematopoietic stem cells niche and bone cell differentiation. Sci Rep (2016) 6:25964. doi:10.1038/srep25964
135. Qiu Z, Yuan W, Chen T, Zhou C, Liu C, Huang Y, et al. HMGCR positively regulated the growth and migration of glioblastoma cells. Gene (2016) 576 (1 Pt 1):22-7. doi:10.1016/j.gene.2015.09.067
136. Larsson O. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit Rev Oncol Hematol (1996) 22(3):197-212. doi:10.1016/ 1040-8428(96)00193-X
137. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) (2004) 229(7):567-85. doi:10.1177/ 153537020422900701
138. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A (2010) 107(34):15051-6. doi:10.1073/ pnas.0910258107
139. Butt S, Butt T, Jirström K, Hartman L, Amini RM, Zhou W, et al. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy. Ann Surg Oncol (2014) 21(9):2911-9. doi:10.1245/s10434-014-3708-4
140. Chushi L, Wei W, Kangkang X, Yongzeng F, Ning X, Xiaolei C. HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene (2016) 587(1):42-7. doi:10.1016/j.gene.2016.04.029
141. Singh R, Yadav V, Kumar S, Saini N. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci Rep (2015) 5:17454. doi:10.1038/srep17454
142. Blank CU, Haanen JB, Ribas A, Schumacher TN. Cancer immunology. The "cancer immunogram". Science (2016) 352(6286):658-60. doi:10.1126/ science.aaf2834
143. Pandya PH, Murray ME, Pollok KE, Renbarger JL. The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res (2016) 2016:4273943. doi:10.1155/2016/4273943
144. Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum (2011) 63(7):1961-71. doi:10.1002/art.30344
145. Drouot L, Allenbach Y, Jouen F, Charuel JL, Martinet J, Meyer A, et al. Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther (2014) 16(1):R39. doi:10.1186/ar4468
146. Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford) (2016) 55(6):991-9. doi:10.1093/rheumatology/kev444
147. Arouche-Delaperche L, Allenbach Y, Amelin D, Preusse C, Mouly V, Mauhin W, et al. Pathogenic role of anti-SRP and anti-HMGCR antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol (2017) 81(4):538-48. doi:10.1002/ana.24902
148. Mohassel P, Rosen P, Casciola-Rosen L, Pak K, Mammen AL. Expression of the dermatomyositis autoantigen transcription intermediary factor 1? in regenerating muscle. Arthritis Rheumatol (2015) 67(1):266-72. doi:10.1002/art.38863